Clinical Study
Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease
| | Characteristic | Total
(%) or mean (SD) |
| | Mean age, yrs, (SD) | 72.4 (9.2) | | Male, (%) | 114 (59.1) | | White, (%) | 152 (78.8) | | College education, (%) | 62 (32.1) | | Married, (%) () | 145 (76.3) | | Employed full/part-time (%) | 35 (18.1) | | Mean duration of PD, yrs, (SD) | 5.2 (2.3) | | Mean Hoehn and Yahr stage, (SD) | 2.7 (0.8) | | Hoehn and Yahr stage, (%) | | | Stage 1: Unilateral disease | 24 (12.8) | | Stage 1.5: Unilateral plus axial involvement | 10 (5.3) | | Stage 2: Bilateral disease, without impairment of balance | 72 (38.8) | | Stage 2.5: Mild bilateral disease with recovery on pull test | 41 (21.8) | | Stage 3: Mild-to-moderate bilateral disease; some postural instability; physically independent. | 26 (13.8) | | Stage 4: Severe disability; still able to walk or stand unassisted | 9 (4.8) | | Stage 5: Wheelchair bound or bedridden unless aided | 5 (2.7) | | Medication status, (%)* | | | Levodopa only | 67 (34.9) | | Levodopa and any other medication | 108 (56.3) | | Dopamine agonists without levodopa | 17 (8.9) | | PD subtype, (%) | | | Tremor-dominant | 33 (17.1) | | Akinetic rigid | 142 (73.6) | | Mixed | 18 (9.3) |
|
|
* One subject excluded because they were on MAO-B inhibitors alone.
|
